This acquisition strengthens Biocon Biologics’ commitment to expand affordable access to lifesaving biosimilars worldwide, thus addressing global health inequities.
This acquisition provides Biocon Biologics direct commercial presence in advanced markets as well as several emerging markets.
The integration of Viatris’ direct commercial capabilities and supporting infrastructure in the advanced markets and several emerging markets complements Biocon Biologics’ existing capabilities in R&D and global scale manufacturing of biosimilars.
Biocon Biologics will recognize the combined revenue & associated profits from the acquired collaboration biosimilars with immediate effect, a step-up from the existing profit share arrangement.
This acquisition will bring Biocon Biologics closer to patients, customers, and payors in the advanced markets and several emerging markets.
An ‘end to end’ integrated biosimilars organization, Biocon Biologics aspires to expand access and enhance the quality of experience of customers, partners and patients.